This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by MacIntyre, P. D. Articles by Hillis, W. S. Search for Related Content PubMed PubMed Citation Articles by MacIntyre, P. D. Articles by Hillis, W. S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Circulation, Vol 87, 401-405, Copyright © 1993 by American Heart Association

ARTICLES

Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation

PD MacIntyre, B Bhargava, KJ Hogg, JD Gemmill and WS Hillis
Department of Medicine and Therapeutics, University of Glasgow, Scotland.

BACKGROUND. Sumatriptan (GR43175) is a selective 5-hydroxytryptamine (5HT1) receptor agonist effective in the acute treatment of migraine. Recent in vitro experiments suggest that it has vasoactive properties in vascular beds distinct from the cerebral circulation. The object of this study was to assess the vasoactive effects of the standard 6-mg subcutaneous dose of sumatriptan used in migraine on the systemic and pulmonary circulations and the coronary artery vasculature. METHODS AND RESULTS. Ten patients undergoing diagnostic coronary arteriography were studied with digital subtraction angiography and invasive hemodynamic monitoring. After subcutaneous injection of sumatriptan, there was no significant change in heart rate or ECG morphology. There was a significant rise in the systemic (20%, p < 0.05 by ANOVA) and pulmonary artery (40%, p < 0.05 by ANOVA) pressures. There was no change in cardiac output, but there was a significant increase in total systemic (27%, p < 0.05) and total pulmonary vascular resistance (40%, p < 0.05). Sumatriptan caused a significant reduction (p < 0.001 by ANOVA) in mean absolute coronary artery diameter, from 4.36 +/- 1.60 mm at baseline to 3.67 +/- 1.49 mm (16%) at 10 minutes and to 3.63 +/- 1.49 mm (17%) at 30 minutes after injection. There were no clinical sequelae. CONCLUSIONS. Sumatriptan, a 5HT1 receptor agonist administered by the subcutaneous route, causes a vasopressor response in the systemic and pulmonary arterial circulations and coronary artery vasoconstriction.

This article has been cited by other articles:

				G. C. Hall, M. M. Brown, J. Mo, and K. D. MacRae Triptans in migraine: The risks of stroke, cardiovascular disease, and death in practice Neurology, February 24, 2004; 62(4): 563 - 568. [Abstract] [Full Text] [PDF]

				J. F. Knudsen, B. Friedman, M. Chen, and J. E. Goldwasser Ischemic Colitis and Sumatriptan Use Arch Intern Med, September 28, 1998; 158(17): 1946 - 1948. [Abstract] [Full Text]

				A. MaassenVanDenBrink, M. Reekers, W. A. Bax, M. D. Ferrari, and P. R. Saxena Coronary Side-Effect Potential of Current and Prospective Antimigraine Drugs Circulation, July 7, 1998; 98(1): 25 - 30. [Abstract] [Full Text] [PDF]

				J. P. Ottervanger, H. A. Valkenburg, D. E. Grobbee, and B. H. C. Stricker Characteristics and Determinants of Sumatriptan-Associated Chest Pain Arch Neurol, November 1, 1997; 54(11): 1387 - 1392. [Abstract] [PDF]

				K.M.A. Welch Drug Therapy of Migraine N. Engl. J. Med., November 11, 1993; 329(20): 1476 - 1483. [Full Text]